ACADL suppresses PD-L1 expression to prevent cancer immune evasion by targeting Hippo/YAP signaling in lung adenocarcinoma

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Medical Oncology

• Publication date

  2023-03-17

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12032-023-01978-yPMID 36929466
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• First-Line Immunotherapy for Non-Small-Cell Lung Cancer.

  2022cited by this paper
• The activation of PPARγ enhances Treg responses through up-regulating CD36/CPT1-mediated fatty acid oxidation and subsequent N-glycan branching of TβRII/IL-2Rα

  2022cited by this paper
• ACADL Functions as a Tumor Suppressor in Hepatocellular Carcinoma Metastasis by Inhibiting Matrix Metalloproteinase 14

  2022cited by this paper
• Hallmarks of Cancer: New Dimensions.

  2022cited by this paper
• Lung cancer

  2021cited by this paper
• The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation

  2021cited by this paper
• PD-L1 as a biomarker of response to immune-checkpoint inhibitors

  2021influential reference
• ACADL plays a tumor-suppressor role by targeting Hippo/YAP signaling in hepatocellular carcinoma

  2020influential reference
• First line Immunotherapy for Non-Small Cell Lung Cancer

  2020cited by this paper
• The Crosstalk Between Hippo-YAP Pathway and Innate Immunity

  2020cited by this paper
• A Prognostic Model Based on Six Metabolism-Related Genes in Colorectal Cancer

  2020cited by this paper
• PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition

  2019cited by this paper
• Mechanisms Controlling PD-L1 Expression in Cancer.

  2019cited by this paper
• Cancer statistics, 2019

  2019cited by this paper
• The Hippo Pathway: Biology and Pathophysiology.

  2019cited by this paper
• WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer

  2019cited by this paper
• Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells

  2019influential reference
• FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway

  2019influential reference
• Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities.

  2019cited by this paper
• Acyl-CoA dehydrogenase long chain expression is associated with esophageal squamous cell carcinoma progression and poor prognosis

  2018cited by this paper
• Cancer immunotherapy using checkpoint blockade

  2018cited by this paper
• YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma

  2018influential reference
• Leading Edge Review Primary , Adaptive , and Acquired Resistance to Cancer Immunotherapy

  2017cited by this paper
• YAP activates the Hippo pathway in a negative feedback loop

  2017cited by this paper
• Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

  2017influential reference
• The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity.

  2016cited by this paper
• Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype

  2016cited by this paper
• Mechanisms of Hippo pathway regulation

  2016influential reference
• Targeting YAP-dependent MDSC infiltration impairs tumor progression

  2015cited by this paper
• Immune evasion in cancer: Mechanistic basis and therapeutic strategies.

  2015cited by this paper
• YAP activates the Hippo pathway in a negative feedback loop

  2015cited by this paper
• A Protein Profile of Visceral Adipose Tissues Linked to Early Pathogenesis of Type 2 Diabetes Mellitus*

  2014cited by this paper
• A Novel Small Molecule Aurora Kinase Inhibitor Attenuates Breast Tumor–Initiating Cells and Overcomes Drug Resistance

  2014cited by this paper
• HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression.

  2014influential reference
• Hydrodynamic delivery of interleukin 15 gene promotes resistance to high fat diet-induced obesity, fatty liver and improves glucose homeostasis

  2014cited by this paper
• The Hippo pathway and human cancer

  2013influential reference
• Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer

  2013cited by this paper
• Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling.

  2012cited by this paper
• Hippo signaling: growth control and beyond

  2011cited by this paper
• Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity.

  2011cited by this paper
• Mitochondrial long chain fatty acid beta-oxidation in man and mouse.

  2009cited by this paper
• Lung cancer.

  2008cited by this paper
• Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance

  2007cited by this paper
• Long-chain acyl-CoA dehydrogenase is a key enzyme in the mitochondrial beta-oxidation of unsaturated fatty acids.

  2000cited by this paper
• Lung cancer.

  1990cited by this paper

• Multi-omics mapping identifies CYBA-mediated mitochondrial dysfunction driving macrophage polarization and ferroptosis via Nrf2 pathway in atherosclerosis

  2026cites this paper
• Integrated transcriptomic analysis and experimental validation identify ACADL as a mitochondrial tumor suppressor via the FOXO3a/PUMA axis in lung adenocarcinoma

  2026cites this paper
• Fatty acid metabolic reprogramming in the tumor microenvironment: Unraveling mechanisms and therapeutic prospects

  2025cites this paper
• SLPI⁺ AT2‐Like Cells Orchestrate Lung Adenocarcinoma Invasion via Wnt Pathway Activation and Stromal Crosstalk in a Spatially Defined Margin Niche

  2025cites this paper
• MISP promotes the progression of lung adenocarcinoma through Inhibition of the Hippo signaling pathway

  2025cites this paper
• EBF3 transcriptionally activates ACADL to block the Hippo/YAP signaling pathway and inhibits breast cancer progression.

  2025cites this paper
• Structural basis for expanded substrate specificities of human long chain acyl-CoA dehydrogenase and related acyl-CoA dehydrogenases

  2024cites this paper
• Exploring the impact of flavin homeostasis on cancer cell metabolism.

  2024cites this paper
• Mitochondrial cholesterol metabolism related gene model predicts prognosis and treatment response in hepatocellular carcinoma

  2024cites this paper
• Effect of Transferrin‐Modified Fe3O4 Nanoparticle Targeted Delivery miR‐15a‐5p Combined With Photothermal Therapy on Lung Cancer

  2024cites this paper
• The impact of different levels of wheat diets on hepatic oxidative stress, immune response, and lipid metabolism in Tibetan sheep (Ovis aries)

  2024cites this paper
• ACADL-YAP axis activity in non-small cell lung cancer carcinogenicity

  2024cites this paper
• Structural Basis for Expanded Substrate Specificities of Human Long Chain Acyl-CoA Dehydrogenase and Related Acyl- CoA Dehydrogenases

  2024cites this paper
• Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine

  2024cites this paper
• Integrated bioinformatics and machine learning analysis identify ACADL as a potent biomarker of reactive mesothelial cells.

  2024cites this paper
• YAP at the Crossroads of Biomechanics and Drug Resistance in Human Cancer

  2023cites this paper